ALC Stock Recent News

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

It's rare to find a high-growth foreign company that isn't stuck in a big downtrend. While ALC shares are down sharply year-on-year, its valuation is not so bad considering impressive EPS growth.

Alcon Inc. (NYSE:ALC ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Dan Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Julien Dormois - BNP Paribas Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Markets Jeff Johnson - Baird Cecilia Furlong - Morgan Stanley Joanne Wuensch - Citi Falko Friedrichs - Deutsche Bank Zach Weiner - Jeffries Operator Greetings. And welcome to the Alcon Third Quarter 2022 Earnings Call.

Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.

Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples are less attractive to peers.

New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.

Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million appeared first on Investor's Business Daily.

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

Alcon Inc. (NYSE:ALC ) Q2 2022 Results Conference Call August 10, 2022 8:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Zach Weiner - Jeffries Chris Cooley - Stephens Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Ryan Zimmerman - BTIG Cecilia Furlong - Morgan Stanley Jeff Johnson - Baird Julien Dormois - BNP Paribas David Adlington - JPMorgan Operator Greetings and welcome to the Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.